Allianz Asset Management Gmb H Exelixis, Inc. Transaction History

Allianz Asset Management Gmb H

$62.9 Billion
Q1 2024

A detailed history of Allianz Asset Management Gmb H transactions in Exelixis, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 173,312 shares of EXEL stock, worth $3.84 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

173,312

Previous 124,724 38.96%

Holding current value

$3.84 Million

Previous $2.99 Million 37.43%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $980,019 - $1.16 Million	48,588 Added 38.96%	173,312 $4.11 Million
Q4 2023 Feb 12, 2024	BUY	$19.25 - $24.13 $264,148 - $331,111	13,722 Added 12.36%	124,724 $2.99 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $195,331 - $233,289	-10,259 Reduced 8.46%	111,002 $2.43 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $23.3 Million - $26.2 Million	-1,281,108 Reduced 91.35%	121,261 $2.32 Million
Q1 2023 May 11, 2023	BUY	$16.3 - $19.41 $25,346 - $30,182	1,555 Added 0.11%	1,402,369 $27.2 Million

Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $2.69 Million - $3.13 Million	-180,111 Reduced 11.39%	1,400,814 $22.5 Million
Q3 2022 Nov 08, 2022	BUY	$15.68 - $22.27 $1.02 Million - $1.45 Million	65,213 Added 4.3%	1,580,925 $24.8 Million
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $4.7 Million - $6.24 Million	269,636 Added 21.64%	1,515,712 $31.6 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $2.13 Million - $2.84 Million	125,303 Added 11.18%	1,246,076 $28.2 Million
Q4 2021 Feb 11, 2022	BUY	$15.84 - $21.88 $96,624 - $133,468	6,100 Added 0.55%	1,120,773 $20.5 Million
Q3 2021 Nov 10, 2021	BUY	$16.3 - $21.14 $11.7 Million - $15.1 Million	715,373 Added 179.16%	1,114,673 $23.6 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $7.17 Million - $10.2 Million	399,300 New	399,300 $7.28 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $738,174 - $995,472	-40,140 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $1.73 Million - $2.26 Million	-83,726 Reduced 67.59%	40,140 $982,000
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $1.01 Million - $1.68 Million	61,286 Added 97.93%	123,866 $2.94 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $155,849 - $234,960	10,778 Added 20.81%	62,580 $1.08 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $512,569 - $639,105	33,833 Added 188.29%	51,802 $913,000
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $549,352 - $703,780	-31,072 Reduced 63.36%	17,969 $318,000
Q2 2019 Aug 08, 2019	SELL	$18.93 - $24.75 $2.04 Million - $2.66 Million	-107,570 Reduced 68.69%	49,041 $1.05 Million
Q1 2019 May 13, 2019	SELL	$19.6 - $24.76 $113,738 - $143,682	-5,803 Reduced 3.57%	156,611 $3.73 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $2.73 Million - $4.36 Million	-199,966 Reduced 55.18%	162,414 $3.18 Million
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $7.38 Million - $10.4 Million	-465,212 Reduced 56.21%	362,380 $6.42 Million
Q2 2018 Aug 13, 2018	SELL	$18.56 - $22.45 $5.44 Million - $6.58 Million	-293,024 Reduced 26.15%	827,592 $17.8 Million
Q1 2018 May 14, 2018	SELL	$22.15 - $31.89 $550,427 - $792,466	-24,850 Reduced 2.17%	1,120,616 $24.8 Million
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $1.29 Million - $1.65 Million	-53,383 Reduced 4.45%	1,145,466 $34.8 Million
Q3 2017 Nov 13, 2017	SELL	$23.35 - $29.24 $1.9 Million - $2.38 Million	-81,405 Reduced 6.36%	1,198,849 $29 Million
Q2 2017 Aug 14, 2017	BUY	N/A	249,262 Added 24.18%	1,280,254 $31.5 Million
Q1 2017 Apr 17, 2019	SELL	N/A	-60,551 Reduced 5.55%	1,030,992 $22.2 Million
Q4 2016 Apr 17, 2019	BUY	N/A	253,123 Added 30.19%	1,091,543 $16.3 Million
Q3 2016 Apr 17, 2019	BUY	N/A	838,420	838,420 $10.4 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.13B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.

Account

Allianz Asset Management Gmb H Exelixis, Inc. Transaction History